EURONEXT-PAR$DBVT
DBV Technologies · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
DBV Technologies reported its full year 2023 financial results and business update.
DBV Technologies reported cash and cash equivalents of $141.4 million as of December 31, 2023. The company experienced a net loss of $72.7 million for the year ended December 31, 2023. They are focused on completing enrollment in VITESSE, their Phase 3 efficacy and safety trial in children.
- Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old).
- Strengthened executive leadership team in preparation for BLA submission.
- Confirmed EPITOPE study is sufficient for clinical portion of a BLA.
- Initiated VITESSE, a Phase 3 clinical trial to evaluate the efficacy and safety of the circular Viaskin Peanut patch in peanut-allergic children aged 4 through 7 years.
Headline financials
Revenue & EPS history
DBV Technologies · Revenue · Quarterly
$2.44M
Forward guidance
DBV Technologies anticipates several key events in 2024, including initiating COMFORT Toddlers and COMFORT Children, screening the last patient in VITESSE, and announcing top-line efficacy and safety data from year three of EPITOPE.
Tailwinds
- Initiate COMFORT Toddlers, the six-month supplemental safety trial in support of BLA.
- Screen last patient in VITESSE, now expected by Q3 2024.
- Initiate COMFORT Children, the six-month supplemental safety trial in support of BLA.
- Announce top-line efficacy and safety data from year three of EPITOPE, corresponding to end-of-study results for participants completing three years of active treatment.
- Publish manuscripts including invited reviews in peer-reviewed scientific journals and submit abstracts on new data at upcoming scientific conferences.
Headwinds
- The Company has incurred operating losses and negative cash flows from operations since inception.
- The Company’s available cash and cash equivalents are not projected to be sufficient to support its operating plan for at least the next 12 months.
- There is substantial doubt regarding the Company’s ability to continue as a going concern.
- The Company intends to seek additional capital through debt and equity offerings.
- Uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+11.4%
Avg return
30 days after
47%
20 / 43 earnings
Positive
+21.6%
Q4 2018
Best reaction
-29.8%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | -4.3% | -83.9% | |
| Q3 2025 | -1.2% | -5.4% | -1.4% | |
| Q1 2025 | -4.4% | +4.2% | -7.3% | |
| Q4 2024 | +7.5% | +0.9% | -1.4% | |
| Q3 2024 | -2.5% | -11.3% | +380.9% | |
| Q1 2024 | +3.7% | -14.0% | -15.4% | |
| Q4 2023 | +1.2% | +1.1% | -9.6% | |
| Q3 2023 | -2.9% | -1.9% | -29.5% | |
| Q2 2023 | +1.9% | -2.5% | -3.2% | |
| Q1 2023 | +5.8% | +4.5% | +27.6% | |
| Q4 2022 | -0.7% | +4.1% | +16.6% | |
| Q3 2022 | +2.7% | +2.0% | -9.5% | |
| Q2 2022 | -5.5% | +3.5% | -21.2% | |
| Q1 2022 | -1.6% | +6.2% | +19.4% | |
| Q4 2021 | +3.1% | +0.8% | +22.3% | |
| Q3 2021 | -29.8% | -40.9% | -41.3% | |
| Q2 2021 | -4.4% | -8.1% | +7.7% | |
| Q1 2021 | -1.1% | +0.6% | +21.4% | |
| Q4 2020 | -0.4% | +2.9% | +86.2% | |
| Q3 2020 | +0.0% | -3.5% | -16.4% | |
| Q2 2020 | -3.0% | -3.5% | -16.8% | |
| Q1 2020 | -7.7% | -7.7% | +53.6% | |
| Q4 2019 | -1.2% | +3.6% | -11.7% | |
| Q3 2019 | -0.4% | +4.0% | -13.7% | |
| Q2 2019 | +5.5% | +26.5% | +17.2% | |
| Q1 2019 | -1.7% | +14.3% | +26.5% | |
| Q4 2018 | +21.6% | +34.8% | +16.3% | |
| Q3 2018 | -2.7% | -14.8% | -18.9% | |
| Q2 2018 | -1.9% | -0.1% | -8.2% | |
| Q1 2018 | -1.3% | +3.7% | -4.9% | |
| Q4 2017 | +3.5% | +7.8% | -4.7% | |
| Q3 2017 | +5.5% | -3.4% | +17.2% | |
| Q2 2017 | +1.4% | +1.3% | +25.0% | |
| Q1 2017 | -0.3% | -1.7% | +1.3% | |
| Q4 2016 | -1.1% | -0.4% | -1.0% | |
| Q3 2016 | +1.1% | +1.9% | -2.7% | |
| Q2 2016 | +3.5% | +0.6% | +6.8% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro